Darunavir is a substrate of CYP3A; it is also an inhibitor of CYP3A, CYP2D6 and P-gp.
Cobicistat is an inhibitor of CYP3A and CYP2D6, and it is an inhibitor of the following transporters: P-gp, BCRP, OATP1B1 and OATP1B3. It is metabolized by CYP3A and CYP2D6.
Tenofovir alafenamide is a substrate of cathepsin A, CYP3A and P-gp.
Target
HIV protease [KO:K22599] HIV-1 reverse transcriptase [KO:K24802]
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AR Antivirals for treatment of HIV infections, combinations
J05AR22 Emtricitabine, tenofovir alafenamide, darunavir and cobicistat
D11382 Darunavir, cobicistat, emtricitabine and tenofovir alafenamide <JP/US>
USP drug classification [BR:br08302]
Antivirals
Anti-HIV Combinations
Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide Fumarate
D11382 Darunavir, cobicistat, emtricitabine and tenofovir alafenamide
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
62 Chemotherapeutics
625 Antivirals
6250 Antivirals
D11382 Darunavir, cobicistat, emtricitabine and tenofovir alafenamide
Drug groups [BR:br08330]
Antiviral
DG03107 Anti-HIV agent
D11382 Darunavir, cobicistat, emtricitabine and tenofovir alafenamide
Drug classes [BR:br08332]
Antiviral
DG03107 Anti-HIV agent
D11382 Darunavir, cobicistat, emtricitabine and tenofovir alafenamide
Antimicrobials [BR:br08307]
Antivirals
Polyprotein cleavage inhibitor
HIV protease inhibitor
D11382 Darunavir, cobicistat, emtricitabine and tenofovir alafenamide <JP/US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11382
